Neutral
Boston Scientific stock hits 52-week low at 47.16 USD
Boston Scientific's stock has dropped to a 52-week low of $47.16, marking a 51% decline over the past year and 47% in the last six months. Despite thi...
BSX
--
--
--
--
Price Chart (30 Days)
Ad Space
Analyst Sentiment
Bullish (13)
Neutral (11)
Bearish (3)
Latest BSX News
Neutral
Neutral
BTIG Remains Bullish On Boston Scientific (BSX); Check Out What It Says About The Stock
Boston Scientific (BSX) has experienced a significant de-rating in 2026, with share prices down nearly 50%, despite most analysts maintaining bullish ...
Neutral
Is Boston Scientific (BSX) One of the Best Healthcare Stocks to Buy With the Highest Upside Potential?
Boston Scientific (BSX) is identified as one of the best healthcare stocks with high upside potential, despite recent price target cuts by TD Cowen an...
Bearish
Truist cuts Boston Scientific stock price target on Watchman slowdown
Truist Securities has lowered its price target for Boston Scientific Corp. (NYSE:BSX) to $64 from $85, while maintaining a Buy rating, due to a slowdo...
Bullish
Marietta medical startup gets $1.5 billion investment from Boston company
Boston Scientific is investing $1.5 billion in MiRus, a Marietta-based heart-valve startup, a year after exiting the heart valve replacement market. T...
Bearish
Wolfe Research Downgrades Boston Scientific Corporation (BSX) To Peer Perform
Wolfe Research downgraded Boston Scientific Corporation (BSX) from Outperform to Peer Perform, ending a four-year bullish outlook. This decision follo...
Neutral
Canaccord lowers Boston Scientific stock price target on Watchman slowdown
Canaccord has lowered its price target for Boston Scientific (NYSE:BSX) from $71 to $70, while maintaining a Buy rating, due to anticipated slowdowns ...
Bullish
Unusual Options Activity Points to Boston Scientific Stock as a Hot M&A Target
Unusual options activity in Boston Scientific (BSX) suggests it could be a significant merger and acquisition (M&A) target, especially after a recent ...
Neutral
Boston Scientific’s $1.5B bet signals heart valve market battle
Boston Scientific has made a significant $1.5 billion investment, signaling a major move into the heart valve market. This action indicates a direct c...
Bearish
Boston Scientific falls on Watchman headwinds (BSX:NYSE)
Boston Scientific's shares fell by approximately 10% to a 52-week low on Wednesday morning. This decline followed the MedTech company's announcement o...
Neutral
Boston Scientific stock tumbles 6% after guidance cut
Boston Scientific's stock fell over 6% after the company lowered its full-year organic growth guidance to 6.5% to 8%, citing a decline in standalone W...
Bullish
Boston Scientific Corp. stock (US10117L1017): Q1 beat and raised guidance keep medtech on investors radar
Boston Scientific Corp. (US10117L1017) reported a strong Q1 2026 with an earnings beat and raised guidance, maintaining investor interest. The stock i...
Neutral
Boston Scientific Corporation $BSX Shares Sold by HighTower Advisors LLC
HighTower Advisors LLC reduced its position in shares of Boston Scientific Corporation (NYSE:BSX – Free Report) by 5.5% during the fourth quarter, acc...
Neutral
ProShare Advisors LLC Has $29.19 Million Position in Boston Scientific Corporation $BSX
ProShare Advisors LLC grew its holdings in Boston Scientific Corporation (NYSE:BSX – Free Report) by 9.3% in the fourth quarter, according to its most...
Bullish
Boston Scientific’s strategic investment in MiRus includes option to acquire TAVR system
Boston Scientific has invested $1.5 billion in MiRus LLC for an approximately 34% equity stake, securing an exclusive option to acquire the MiRus TAVR...
Neutral
Baird Maintains Bullish View on Boston Scientific (BSX) Despite Lower Target
Baird has reiterated an Outperform rating on Boston Scientific (BSX) but lowered its price target to $75 from $78, following the company's re-entry in...
Bullish
Boston Scientific Corp. stock (US10117L1017): market eyes next catalysts after recent updates
Boston Scientific Corp. remains a significant player in the medical technology sector, focusing on minimally invasive cardiovascular and interventiona...
Bullish
Trial of new heart device leaves 93% free of major cardiac events
Boston Scientific's FRACTURE IDE trial for its SEISMIQ 4CE Coronary IVL Catheter met its primary safety and effectiveness endpoints, showing 93.3% fre...
Bullish
Boston Scientific stock gains on $2B share buyback plan
Boston Scientific Corp (BSX) shares rose 2.1% in premarket trading after the company announced a $2 billion accelerated share repurchase agreement. Th...
Bullish
Boston Scientific stock gains on $2B share buyback plan
Boston Scientific's shares rose after the company announced a $2 billion accelerated share repurchase agreement, part of a larger $5 billion authoriza...
Research BSX on:
Ad Space